Post by Nadica (She/Her) on Aug 25, 2024 21:09:07 GMT
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge - Published Oct 23, 2020
Highlights
•Full-length SARS-CoV-2 prefusion spike with Matrix-M™ (NVX-CoV2373) vaccine.
•Induced hACE2 receptor blocking and neutralizing antibodies in macaques.
•Vaccine protected against SARS-CoV-2 replication in the nose and lungs.
•Absence of pulmonary pathology in NVX-CoV2373 vaccinated macaques.
Abstract
There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion conformation. Cynomolgus macaques (Macaca fascicularis) immunized with NVX-CoV2373 and the saponin-based Matrix-M™ adjuvant induced anti-S antibody that was neutralizing and blocked binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2, immunized macaques were protected against upper and lower infection and pulmonary disease. These results support ongoing phase 1/2 clinical studies of the safety and immunogenicity of NVX-CoV2327 vaccine (NCT04368988).
Keywords: SARS-CoV-2, COVID-19, Spike glycoprotein, NVX-CoV2373 nanoparticles, Matrix-M adjuvant, Nonhuman primate
Highlights
•Full-length SARS-CoV-2 prefusion spike with Matrix-M™ (NVX-CoV2373) vaccine.
•Induced hACE2 receptor blocking and neutralizing antibodies in macaques.
•Vaccine protected against SARS-CoV-2 replication in the nose and lungs.
•Absence of pulmonary pathology in NVX-CoV2373 vaccinated macaques.
Abstract
There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion conformation. Cynomolgus macaques (Macaca fascicularis) immunized with NVX-CoV2373 and the saponin-based Matrix-M™ adjuvant induced anti-S antibody that was neutralizing and blocked binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2, immunized macaques were protected against upper and lower infection and pulmonary disease. These results support ongoing phase 1/2 clinical studies of the safety and immunogenicity of NVX-CoV2327 vaccine (NCT04368988).
Keywords: SARS-CoV-2, COVID-19, Spike glycoprotein, NVX-CoV2373 nanoparticles, Matrix-M adjuvant, Nonhuman primate